Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

The agent security gap: 54% of enterprises have already had an AI agent incident, and most still let agents share credentials

View original at venturebeat.com
VentureBeat AI - Enterprise Ai Title: The agent security gap: 54% of enterprises have already had an AI agent incident, and most still let agents share credentials Date: 2026-07-16 19:02 Source: https://venturebeat.com/ai/the-agent-security-gap-54-of-enterprises-have-already-had-an-ai-agent-incident-and-most-still-let-…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Satisfaction with agent security tooling averages 4.2 out of 5 overall, and 4.1 for value for money.

    60% confidence
  • OpenAI's guardrails lead agent security tooling usage at 51%, and 82% of enterprises name a provider-native offering as their single primary security layer.

    60% confidence
  • More than half of organizations (54%) have already experienced a confirmed agent security incident (18%) or a near-miss caught before harm (36%).

    60% confidence
  • Organizations with credential sharing anywhere in the fleet were hit with an incident or near-miss at 63.5% (47 of 74), versus 40.9% (9 of 22) for organizations where every agent has its own scoped identity.

    60% confidence
  • Twelve percent of respondents include an agent-identity product anywhere in their consideration set, and this figure is essentially unchanged among credential-sharing organizations that have already had an incident.

    60% confidence
  • Only about a third (32%) of enterprises give every agent its own scoped, managed identity; the rest report shared credentials somewhere in the agent fleet.

    60% confidence
  • Among organizations that have been hit by an incident, 42.1% plan to adopt, add, or replace agent security tooling within 90 days, versus 14.0% of organizations with no incident; after a confirmed incident this rises to 52.6%.

    60% confidence
  • Incident/near-miss rate rises from 49% in mid-market companies (101-1,000 employees) to 63% at larger enterprises (above 1,000 employees), while sandbox isolation falls from 35% to 20% and satisfaction drops from 4.36 to 3.97.

    60% confidence
  • Only three in ten enterprises (30%) isolate their highest-risk agents in sandboxes.

    60% confidence
  • The most common agent security budget allocation is 6-10% (46%), a third of enterprises (34%) spend 5% or less, and only 24% spend more than a tenth.

    60% confidence
  • Only 35% of enterprises believe their AI-enabled defenses are ahead of AI-enabled attackers; 53% rate the balance as even or tilted toward the attacker.

    60% confidence
  • A clear majority (59%) of enterprises intend to adopt a new, additional, or replacement agent security solution within twelve months, and 29% within the next quarter.

    60% confidence

Data points we hold from this source

OpenAI · agent security tooling usage rate26 percent
OpenAI · purchase consideration rate34 percent
Anthropic · purchase consideration rate29 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com